068 | The weight is over: How GLP-1 treatment...

The Allianz Global Insurance Report shows that global premiums rose by 7% to reach 6.9 trillion euros in 2025, adding 456 billion euros to the global premium pool. But looking ahead, there are some bigger forces shaping the future of the insurance industry. Join our AI assistants ...  Show more

The number of the week is $1.4 billion — that's how much extra US residential households are paying on their electricity bills per year as a direct result of data-center demand. Against this backdrop, preparing energy infrastructure for AI and addressing community concerns is as ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ...

Apple & Amazon the latest big tech names to report results. The headlines from the company conference calls, and what top tech analyst Gene Munster sees in store for the group. Plus Eli Lilly jumping as its obesity drug sales soar. How the company is moving the needle in the w ...

FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide. Featuring: Sara Heath, executive editor, Xtelligent Healthcare Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent ...  Show more

Dr. Marty Makary has criticized the Food and Drug Administration for being "captured" by Big Food and Big Pharma. Now, the surgeon and former professor is in charge. In an interview with host Jessica Mendoza, the new FDA head talks about food dyes, AI, vaccines and the big change ...  Show more